Cellectis (CLLS) Free Cash Flow Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 31.42% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | 18.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.63% |
| Sep 30, 2025 | 75.21% |
| Jun 30, 2025 | 23.85% |
| Mar 31, 2025 | -36.61% |
| Sep 30, 2024 | 41.94% |
| Jun 30, 2024 | 115.25% |
| Mar 31, 2024 | -27.92% |
| Dec 31, 2023 | 33.90% |
| Sep 30, 2023 | 4.51% |
| Jun 30, 2023 | -31.56% |
| Mar 31, 2023 | -71.00% |
| Sep 30, 2022 | -14.21% |
| Jun 30, 2022 | -7.54% |
| Mar 31, 2022 | 31.64% |
| Sep 30, 2021 | -23.27% |
| Jun 30, 2021 | 17.74% |
| Mar 31, 2021 | 17.07% |
| Dec 31, 2020 | -97.60% |
| Sep 30, 2020 | -8.94% |
| Jun 30, 2020 | 20.47% |
| Mar 31, 2020 | 37.42% |
| Dec 31, 2019 | -7.44% |
| Sep 30, 2019 | -217.30% |
| Jun 30, 2019 | -31.45% |
| Mar 31, 2019 | -12.92% |
| Dec 31, 2018 | -43.92% |
| Sep 30, 2018 | -40.98% |
| Jun 30, 2018 | 11.72% |
| Mar 31, 2018 | -136.45% |